{
  "source": "PA-Notification-Ojjaara.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1419-2\nProgram Prior Authorization/Notification\nMedication Ojjaara™ (momelotinib)\nP&T Approval Date 11/2023, 11/2024\nEffective Date 2/15/2025\n1. Background:\nOjjaara (momelotinib) is a kinase inhibitor indicated for the treatment of intermediate or\nhigh-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera\n(PV) and post-essential thrombocythemia (ET)] with anemia. The National Cancer\nComprehensive Network (NCCN) also recommends Ojjaara for the treatment of lower-risk and\nhigher-risk myelofibrosis, and accelerated/blast phase myeloproliferative neoplasms.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Ojjaara will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Myeloproliferative Neoplasms\n1. Initial Authorization\na. Ojjaara will be approved based on one of the following criteria:\n(1) Diagnosis of symptomatic lower-risk myelofibrosis\n-OR-\n(2) All of the following:\n(a) Diagnosis of higher-risk myelofibrosis\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(b) Presence of symptomatic splenomegaly and/or constitutional symptoms\n-AND-\n(c) One of the following:\ni. Used as continued therapy near the start of conditioning therapy in a\ntransplant candidate\nii. Patient is not a transplant candidate or transplant not currently feasible\n-OR-\n(3) Diagnosis of myelofibrosis-associated anemia\n-OR-\n(4) ",
    "e start of conditioning therapy in a\ntransplant candidate\nii. Patient is not a transplant candidate or transplant not currently feasible\n-OR-\n(3) Diagnosis of myelofibrosis-associated anemia\n-OR-\n(4) Both of the following:\n(a) Diagnosis of accelerated/blast phase myeloproliferative neoplasm\n-AND-\n(b) One of the following:\ni. Used for the improvement of splenomegaly or other disease-related\nsymptoms\nii. Continued treatment as a single agent near to the start of conditioning\ntherapy in transplant candidates for the improvement of splenomegaly\nand other disease-related symptoms\nAuthorization will be issued for 6 months.\n2. Reauthorization\na. Ojjaara will be approved based on one the following criteria:\n(1) Documentation that patient has evidence of symptom improvement or reduction\nin spleen volume while on Ojjaara\nAuthorization will be issued for 6 months.\n-OR-\n(2) Documentation does not provide evidence of symptom improvement or\nreduction in spleen volume while on Ojjaara, allow for dose titration with\n© 2024 UnitedHealthcare Services, Inc.\n2\ndiscontinuation of therapy\nAuthorization will be issued for 2 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limit may be in place.\n4. References:\n1. Ojjaara [package",
    "is codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limit may be in place.\n4. References:\n1. Ojjaara [package insert]. Durham, NC: GlaxoSmithKline; September 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/ Accessed October 11,\n2024.\nProgram Prior Authorization/Notification – Ojjaara™ (momelotinib)\nChange Control\n11/2023 New program.\n11/2024 Annual review. Modified title of myelofibrosis to myeloproliferative\nneoplasms and updated coverage criteria based on NCCN guidelines.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}